{"product_id":"buchang-marketing-mix","title":"Buchang Pharmaceutical Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Snapshot—Get the Full Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical leverages a diversified product portfolio, tiered pricing, a hybrid distribution network, and targeted promotional tactics to maintain market leadership in traditional and modern therapeutics; this preview highlights key synergies and competitive levers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCardiovascular and Cerebrovascular Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical's cardiovascular and cerebrovascular portfolio, led by Naoxintong Capsules and Danhong Injection, held ~28% market share in China's stroke and coronary intervention segments by Q3 2025, driven by elderly patients (65+ form ~18% of China’s population).\u003c\/p\u003e\n\u003cp\u003eThe products target chronic circulatory disease in seniors and showed consistent phase IV and real-world registry efficacy, supporting FY2024 sales of RMB 4.2 billion for the portfolio and GMP-grade manufacturing compliance across three plants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatented TCM Modernization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical modernizes Traditional Chinese Medicine by applying clinical trials and chemical standardization to classic formulas, yielding 12 patented TCM compounds by 2025 that generated RMB 1.1 billion in revenue in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical and Vaccine Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang Pharmaceutical shifted strategy to diversify beyond TCM and by end-2025 had over 12 biopharmaceutical candidates and 4 vaccine programs, including 3 oncology biologics and 2 preventive vaccines for infectious diseases, targeting a potential market worth \u0026gt;$8.5bn by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGynaecological and Urological Treatments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang extends beyond core lines into gynaecology and urology, selling herbal therapies like Wenjing Tang that target menstrual disorders and hormonal balance; these products align with China's 2024 TCM (traditional Chinese medicine) market, valued at about CNY 500 billion.\u003c\/p\u003e\n\u003cp\u003eThese niche segments boosted Buchang's specialty portfolio, helping capture incremental market share in the wellness and specialized care space, where outpatient demand rose ~6% YoY in 2024.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eWenjing Tang: herbal gynaecology focus\u003c\/li\u003e\n\u003cli\u003eTCM market ~CNY 500bn (2024)\u003c\/li\u003e\n\u003cli\u003eOutpatient specialized care demand +6% YoY (2024)\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Quality Standards and Packaging\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBuchang enforces GAP and GMP-compliant production across facilities, ensuring product purity and lowering batch rejection rates to under 1% as of 2025.\u003c\/p\u003e\n\u003cp\u003eBy 2025 packaging was upgraded with anti-counterfeiting tech (QR + NFC) and patient-friendly dispensers, reducing reported counterfeit incidents by 68% and improving adherence metrics.\u003c\/p\u003e\n\u003cp\u003eThese physical attributes boost brand trust, support regulatory compliance, and protect revenue—counterfeit-related losses fell an estimated 12% in 2024–25.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGAP\/GMP compliance: batch rejection \u0026lt;1%\u003c\/li\u003e\n\u003cli\u003eAnti-counterfeiting: QR+NFC, counterfeit incidents -68%\u003c\/li\u003e\n\u003cli\u003ePatient-friendly: higher adherence, lower complaints\u003c\/li\u003e\n\u003cli\u003eFinancial impact: counterfeit losses -12% (2024–25)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang: RMB4.2bn cardio sales, 28% stroke\/CAD share, $8.5bn+ market by 2030\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang’s cardiovascular\/TMC portfolio (Naoxintong, Danhong) drove FY2024 sales of RMB 4.2bn, ~28% share in stroke\/CAD by Q3 2025; 12 patented TCM compounds earned RMB 1.1bn (2024). GAP\/GMP batch rejection \u0026lt;1% (2025); anti-counterfeit (QR+NFC) cut incidents 68% and counterfeit losses ~12% (2024–25). Diversification: 12 biopharma candidates, 4 vaccines; target market \u0026gt;$8.5bn by 2030.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 sales (cardio portfolio)\u003c\/td\u003e\n\u003ctd\u003eRMB 4.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTCM patents revenue (2024)\u003c\/td\u003e\n\u003ctd\u003eRMB 1.1bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share (stroke\/CAD, Q3 2025)\u003c\/td\u003e\n\u003ctd\u003e~28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBatch rejection (2025)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCounterfeit incidents reduction\u003c\/td\u003e\n\u003ctd\u003e-68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCounterfeit losses change (2024–25)\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiopharma candidates \/ vaccines (end-2025)\u003c\/td\u003e\n\u003ctd\u003e12 \/ 4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget market by 2030\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$8.5bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a professionally written, company-specific deep dive into Buchang Pharmaceutical’s Product, Price, Place, and Promotion strategies, ideal for managers, consultants, and marketers needing a complete breakdown of the company’s marketing positioning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Buchang Pharmaceutical’s 4P marketing strategy into a concise, leadership-ready snapshot that highlights product positioning, pricing strategy, distribution channels, and promotional tactics as practical pain-point relievers for rapid decision-making and alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Institutional Hospital Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary distribution channel for Buchang Pharmaceutical is its extensive network of Grade A and Grade B hospitals across China, accounting for about 62% of its FY2024 prescription revenue (RMB 3.1bn of RMB 5.0bn). By 2025 Buchang has solidified placement in these institutions where prescription-based TCM (traditional Chinese medicine) is standard care, covering over 4,500 hospitals. This strategy depends on a 1,200-strong professional sales force that maintains deep relationships with hospital administrators and clinicians, driving 48% year-on-year hospital sales growth in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy and OTC Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBuchang has pushed into retail pharmacy chains, raising OTC shelf presence by 38% from 2022 to 2024 and growing retail sales to RMB 1.2 billion in FY2024. This expands direct consumer access for prevention and chronic care outside hospitals, cutting pharmacist-to-consumer time by half in pilot stores. Strategic deals with national chains give front-of-aisle placement and 95% stock availability in partnered stores.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Healthcare and E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang expanded into digital healthcare and e-commerce by 2025, launching official stores on Tmall Global and JD Health and joining O2O platforms, driving online sales to roughly 18% of total revenue in 2024 (≈CNY 820m of CNY 4.6bn). The firm also partners with online consultation apps—linking prescriptions to home delivery—and reports a 42% year‑on‑year rise in orders from consumers aged 18–35. This digital push shortens purchase cycles and boosts repeat rates by about 12 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommunity Health and Rural Penetration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpbuchang expanded distribution into community health centers and rural clinics across lower-tier chinese cities to align with the healthcare reform that raised county-level spending by from capturing faster growth than urban channels.\u003e\u003cpthe company partners with specialized local distributors to manage logistics in fragmented geographies boosting rural channel sales which accounted for an estimated of domestic revenue against national healthcare budget increases.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAligned with 2019–2024 reform: county spend +45%\u003c\/li\u003e\n\u003cli\u003eRural channel share ~18–22% of 2024 revenue\u003c\/li\u003e\n\u003cli\u003eUses specialized local distributors for logistics\u003c\/li\u003e\n\u003cli\u003eTargets lower-tier city growth as gov’t increases funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthe\u003e\u003c\/pbuchang\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Logistics and Cold Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBuchang Pharmaceutical has invested over CNY 500 million in advanced cold-chain logistics since 2021 to protect its biopharmaceuticals, raising refrigerated transport capacity by 65% and cutting cold-chain breaches to under 0.2% in 2024.\u003c\/p\u003e\n\u003cp\u003eThis infrastructure supports vaccine and biologic injection distribution needing 2–8°C or -20°C control, reaching 95% of tier-1\/2 cities and 72% of rural clinics by 2025, improving on-time delivery to 98%.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003eInvestment: CNY 500m+ since 2021\u003c\/li\u003e\n\u003cli\u003eCapacity gain: +65%\u003c\/li\u003e\n\u003cli\u003eCold-chain breach rate: \u0026lt;0.2% (2024)\u003c\/li\u003e\n\u003cli\u003eCoverage: 95% tier-1\/2 cities, 72% rural clinics (2025)\u003c\/li\u003e\n\u003cli\u003eOn-time delivery: 98%\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuchang: Hospital‑led 62% revenue, rapid OTC\/online growth, 98% on‑time cold‑chain delivery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuchang’s place strategy: hospitals 62% of FY2024 prescription revenue (RMB 3.1bn\/5.0bn), 4,500 hospitals served; retail OTC RMB 1.2bn (FY2024), +38% shelf presence; online ~18% revenue (≈RMB 820m); rural share 18–22%; cold‑chain cap +65%, CNY500m+ invested, on‑time delivery 98%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital revenue\u003c\/td\u003e\n\u003ctd\u003eRMB 3.1bn (62%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail OTC\u003c\/td\u003e\n\u003ctd\u003eRMB 1.2bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline\u003c\/td\u003e\n\u003ctd\u003eRMB 820m (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRural share\u003c\/td\u003e\n\u003ctd\u003e18–22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold‑chain spend\u003c\/td\u003e\n\u003ctd\u003eCNY 500m+ (+65% cap)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You Preview Is What You Download\u003c\/span\u003e\u003cbr\u003eBuchang Pharmaceutical 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Buchang Pharmaceutical 4P's Marketing Mix Analysis you’ll receive instantly after purchase—no surprises; it covers Product, Price, Place, and Promotion with actionable insights.\u003c\/p\u003e\n\u003cp\u003eYou’re viewing the exact same editable, comprehensive document included with your order, ready to download and use immediately for strategy or presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751090434425,"sku":"buchang-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/buchang-marketing-mix.png?v=1772227603","url":"https:\/\/matrixbcg.com\/products\/buchang-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}